2,108 research outputs found
Disparities in Use of Human Epidermal Growth Hormone Receptor 2–Targeted Therapy for Early-Stage Breast Cancer
Trastuzumab is a key component of adjuvant therapy for stage I to III human epidermal growth factor receptor 2 (HER2)–positive breast cancer. The rates and patterns of trastuzumab use have never been described in a population-based sample. The recent addition of HER2 information to the SEER-Medicare database offers an opportunity to examine patterns of trastuzumab use and to evaluate possible disparities in receipt of trastuzumab
Severe mental illness and chronic kidney disease: a cross-sectional study in the United Kingdom
OBJECTIVE: We investigated the burden of chronic kidney disease (CKD) among patients with
severe mental illness (SMI).
METHODS: We identified patients with SMI among all those aged 25–74 registered in the UK
Clinical Practice Research Datalink as on March 31, 2014. We compared the prevalence of CKD
(two measurements of estimated glomerular filtration rate <60 mL/min/1.73 m2
for ≥3 months)
and renal replacement therapy between patients with and without SMI. For patients with and
without a history of lithium prescription separately, we used logistic regression to examine the
association between SMI and CKD, adjusting for demographics, lifestyle characteristics, and
known CKD risk factors.
RESULTS: The CKD prevalence was 14.6% among patients with SMI and a history of lithium
prescription (n = 4,295), 3.3% among patients with SMI and no history of lithium prescription
(n = 24,101), and 2.1% among patients without SMI (n = 2,387,988; P < 0.001). The prevalence
of renal replacement therapy was 0.23%, 0.15%, and 0.11%, respectively (P = 0.012). Compared
to patients without SMI, the fully adjusted odds ratio for CKD was 6.49 (95% CI 5.84–7.21) for
patients with SMI and a history of lithium prescription and 1.45 (95% CI 1.34–1.58) for patients
with SMI and no history of lithium prescription. The higher prevalence of CKD in patients with SMI
may, in part, be explained by more frequent blood testing as compared to the general population.
CONCLUSION: CKD is identified more commonly among patients with SMI than in the general
population
Severe Mental Illness Among Adults with Atopic Eczema or Psoriasis: Population-Based Matched Cohort Studies within UK Primary Care
BACKGROUND: Existing research exploring associations between atopic eczema (AE) or psoriasis, and severe mental illness (SMI – ie, schizophrenia, bipolar disorder, other psychoses) is limited, with longitudinal evidence particularly scarce. Therefore, temporal directions of associations are unclear. We aimed to investigate associations between AE or psoriasis and incident SMI among adults. METHODS: We conducted matched cohort studies using primary care electronic health records (January 1997 to January 2020) from the UK Clinical Practice Research Datalink GOLD. We identified two cohorts: 1) adults (≥ 18 years) with and without AE and 2) adults with and without psoriasis. We matched (on age, sex, general practice) adults with AE or psoriasis with up to five adults without. We used Cox regression, stratified by matched set, to estimate hazard ratios (HRs) comparing incident SMI among adults with and without AE or psoriasis. RESULTS: We identified 1,023,232 adults with AE and 4,908,059 without, and 363,210 with psoriasis and 1,801,875 without. After adjusting for matching variables (age, sex, general practice) and potential confounders (deprivation, calendar period) both AE and psoriasis were associated with at least a 17% increased hazard of SMI (AE: HR=1.17,95% CI=1.12– 1.22; psoriasis: HR=1.26,95% CI=1.18– 1.35). After additionally adjusting for potential mediators (comorbidity burden, harmful alcohol use, smoking status, body mass index, and, in AE only, sleep problems and high-dose glucocorticoids), associations with SMI did not persist for AE (HR=0.98,95% CI=0.93– 1.04), and were attenuated for psoriasis (HR=1.14,95% CI=1.05– 1.23). CONCLUSION: Our findings suggest adults with AE or psoriasis are at increased risk of SMI compared to matched comparators. After adjusting for potential mediators, associations with SMI did not persist for AE, and were attenuated for psoriasis, suggesting that the increased risk may be explained by mediating factors (eg, sleep problems). Our research highlights the importance of monitoring mental health in adults with AE or psoriasis
Role of Esrrg in the Fibrate-Mediated Regulation of Lipid Metabolism Genes in Human ApoA-I Transgenic Mice
We have used a new ApoA-I transgenic mouse model to identify by global gene expression profiling, candidate genes that affect lipid and lipoprotein metabolism in response to fenofibrate treatment. Multilevel bioinformatical analysis and stringent selection criteria (2-fold change, 0% false discovery rate) identified 267 significantly changed genes involved in several molecular pathways. The fenofibrate-treated group did not have significantly altered levels of hepatic human APOA-I mRNA and plasma ApoA-I compared with the control group. However, the treatment increased cholesterol levels to 1.95-fold mainly due to the increase in high-density lipoprotein (HDL) cholesterol. The observed changes in HDL are associated with the upregulation of genes involved in phospholipid biosynthesis and lipid hydrolysis, as well as phospholipid transfer protein. Significant upregulation was observed in genes involved in fatty acid transport and β-oxidation, but not in those of fatty acid and cholesterol biosynthesis, Krebs cycle and gluconeogenesis. Fenofibrate changed significantly the expression of seven transcription factors. The estrogen receptor-related gamma gene was upregulated 2.36-fold and had a significant positive correlation with genes of lipid and lipoprotein metabolism and mitochondrial functions, indicating an important role of this orphan receptor in mediating the fenofibrate-induced activation of a specific subset of its target genes.National Institutes of Health (HL48739 and HL68216); European Union (LSHM-CT-2006-0376331, LSHG-CT-2006-037277); the Biomedical Research Foundation of the Academy of Athens; the Hellenic Cardiological Society; the John F Kostopoulos Foundatio
The ACUTE (Ambulance CPAP: Use, Treatment effect and economics) feasibility study: a pilot randomised controlled trial of prehospital CPAP for acute respiratory failure
Background: Acute respiratory failure (ARF) is a common and life-threatening medical emergency. Standard prehospital
management involves controlled oxygen therapy and disease-specific ancillary treatments. Continuous positive airway
pressure (CPAP) is a potentially beneficial alternative treatment that could be delivered by emergency medical services.
However, it is uncertain whether this treatment could work effectively in United Kingdom National Health Service (NHS)
ambulance services and if it represents value for money.
Methods: An individual patient randomised controlled external pilot trial will be conducted comparing prehospital CPAP
to standard oxygen therapy for ARF. Adults presenting to ambulance service clinicians will be eligible if they have
respiratory distress with peripheral oxygen saturation below British Thoracic Society (BTS) target levels, despite titrated
supplemental oxygen. Enrolled patients will be allocated (1:1 simple randomisation) to prehospital CPAP (O_two system)
or standard oxygen therapy using identical sealed boxes. Feasibility outcomes will include incidence of recruited eligible
patients, number of erroneously recruited patients and proportion of cases adhering to allocation schedule and
treatment, followed up at 30 days and with complete data collection. Effectiveness outcomes will comprise survival at
30 days (definitive trial primary end point), endotracheal intubation, admission to critical care, length of hospital stay,
visual analogue scale (VAS) dyspnoea score, EQ-5D-5L and health care resource use at 30 days. The cost-effectiveness
of CPAP, and of conducting a definitive trial, will be evaluated by updating an existing economic model. The trial aims
to recruit 120 patients over 12 months from four regional ambulance hubs within the West Midlands Ambulance
Service (WMAS). This sample size will allow estimation of feasibility outcomes with a precision of < 5%. Feasibility and
effectiveness outcomes will be reported descriptively for the whole trial population, and each trial arm, together with
their 95% confidence intervals.
Discussion: This study will determine if it is feasible, acceptable and cost-effective to undertake a full-scale trial
comparing CPAP and standard oxygen treatment, delivered by ambulance service clinicians for ARF. This will inform
NHS practice and prevent inappropriate prehospital CPAP adoption on the basis of limited evidence and at a
potentially substantial cost.
Trial registration: ISRCTN12048261. Registered on 30 August 2017. http://www.isrctn.com/ISRCTN1204826
Understanding business ecosystem using a 6C framework in Internet-of-Things-based sectors
With fast development and application, the Internet of Things (IoT) brings more opportunities to business. This research aims to investigate how IoT could lead to a co-evolving business ecosystem rather than a supply chain. It develops the 6C framework to analyze the data collected from case companies, and identifies three patterns of IoT-based business ecosystem. It also provides a summary of practical implications to guide practitioners building an IoT-based business ecosystem
- …